Yomogi Saccharomyces cerevisiae (boulardii) Probiotic
Price range: $16.80 through $32.80
Probiotic supplement: Saccharomyces cerevisiae (boulardii) HANSEN CBS 5926 yeast strain.
Yomogi heat-stable, pharmaceutical-grade formulation requiring no refrigeration, ideal for travel and antibiotic support.
Christmas & Holiday Dispatch
Same-day dispatch on all orders placed before 2pm (Mon–Fri).
We’re sending orders every day over Christmas, except Christmas Eve and public holidays.
Enjoy Free Express shipping on orders over $175 - we recommend Express during the festive period.
What is Yomogi and who is it for?
Yomogi is a pharmaceutical-grade probiotic containing Saccharomyces cerevisiae (boulardii), a tropical yeast strain with a documented history dating back to the 1920s. Unlike bacterial probiotics that colonise your gut, S. boulardii is a transient yeast that passes through your digestive system while exerting its beneficial effects. This makes it particularly useful during periods when your gut microbiota needs temporary support, especially during or after antibiotic use.
This product makes sense if you’re managing antibiotic-associated diarrhoea, preparing for travel to regions where traveller’s diarrhoea is common, or looking for a heat-stable probiotic that doesn’t require refrigeration. The lyophilised formulation and blister-sealed packaging make it genuinely practical for travel, unlike many probiotics that need careful temperature management.
Fairfield Nutrition Thoughts
Antibiotic-associated diarrhoea (AAD) is one of the most common adverse effects of antibiotic treatment, occurring in 10-30% of patients depending on the antibiotic class. Saccharomyces boulardii (Yomogi) addresses this specific problem as it’s a transient organism that exerts effects as it passes through rather than establishing permanent residence.
The clinical evidence for S. boulardii in AAD is substantial and well-documented, with multiple randomised controlled trials demonstrating reduction in both frequency and severity of diarrhoea. What makes Yomogi’s formulation compelling is the combination of strain specificity (HANSEN CBS 5926 / CNCM I-745, the most researched strain), heat stability eliminating cold-chain dependency, and pharmaceutical-grade blister packaging that maintains viability without refrigeration. This is particularly relevant for Australian consumers managing travel or those in warmer climates where refrigerated probiotics become impractical. It may also prevent the likelihood of travellers’ diarrhoea.
Why This Formulation / How It Works
Yomogi differs from multi-strain bacterial probiotics in a fundamental way: it’s a single-strain yeast designed for temporary support rather than long-term colonisation. The HANSEN CBS 5926 strain is the most extensively researched S. boulardii strain globally, with decades of clinical use and documented mechanisms. This formulation eliminates the need for refrigeration while maintaining minimum 2.5 billion CFU per capsule at batch release, making it genuinely stable at room temperature and suitable for travel without compromising potency.
S. boulardii functions as a transient organism in your digestive tract, meaning it passes through rather than establishing permanent residence. As it moves through your intestines, it exerts several beneficial effects: it produces compounds that support intestinal barrier function, provides competition for pathogenic organisms, and produces short-chain fatty acids that support healthy colonic tissue. This transient nature is actually advantageous during antibiotic use, because the yeast won’t be affected by the antibiotic in the way that beneficial bacteria would be.
Support during antibiotic use: When antibiotics disrupt your gut microbiota, the resulting dysbiosis creates an environment where pathogenic organisms like Clostridioides difficile can establish themselves. S. boulardii reduces this risk by maintaining microbial diversity and supporting intestinal barrier integrity while your beneficial bacterial species recover after antibiotic treatment ends.
Transient yeast mechanism: Unlike bacterial probiotics that attempt to colonise and establish permanent populations, S. boulardii exerts its effects during transit through your digestive system. This means it works effectively even in the presence of antibiotics and doesn’t require your gut to provide the conditions necessary for permanent colonisation.
When to Consider This
This formulation provides targeted support for specific gastrointestinal scenarios. Yomogi makes sense if you’re:
Scenario 1: Starting a course of antibiotics and wanting to reduce the risk of antibiotic-associated diarrhoea, which affects up to 30% of people taking certain antibiotic classes.
Scenario 2: Travelling to regions where traveller’s diarrhoea is common and want a heat-stable probiotic that doesn’t require cold storage or refrigeration during your trip.
Scenario 3: Recovering from recent antibiotic use and experiencing ongoing digestive dysbiosis, as S. boulardii supports beneficial microbiota recovery without being affected by residual antibiotic presence.
Supplement strategy: S. boulardii is typically introduced at the start of antibiotic treatment or 5 days before travel, rather than as ongoing daily support. Many practitioners recommend using it for the duration of antibiotic therapy plus 2 weeks after completion, then transitioning to multi-strain bacterial probiotics once your microbiota has begun recovering. It’s often used alongside dietary support (adequate fibre, fermented foods) and sometimes with prebiotic compounds, though Yomogi can be used independently.
⚠️ Not suitable for: Immunocompromised or hospitalised patients, patients with central venous catheters, hypersensitivity to Saccharomyces cerevisiae or yeast, pregnancy and breastfeeding, lactose intolerance
How to Use
Standard dosage: Adults and children over 6 years take 1 capsule once or twice daily. For children aged 2-6 years, open the capsule and stir the contents into food or liquid.
For traveller’s diarrhoea prevention: Take 1 capsule once or twice daily starting 5 days before departure and continue for the duration of travel.
During antibiotic use: Take 1 capsule once or twice daily. Many practitioners recommend starting this when you begin your antibiotic course and continuing for 2 weeks after completing antibiotics.
Yomogi requires no refrigeration due to its lyophilised formulation, making it genuinely convenient for travel or storage in warm environments. Each capsule contains a minimum of 2.5 billion CFU at batch release. Always follow your healthcare professional’s specific recommendations, particularly if you have any pre-existing conditions or are taking other medications.
Ingredients
Per capsule:
Saccharomyces cerevisiae (boulardii) HANSEN CBS 5926 / CNCM I-745: 250 mg (minimum 2.5 billion CFU at batch release)
Other ingredients: Capsule (hypromellose), microcrystalline cellulose
Allergen information: Contains lactose. Free from common allergens including gluten, soy, and dairy (aside from lactose content).
Common Questions
How is S. boulardii different from the multi-strain probiotics I’ve seen?
S. boulardii is a yeast, not a bacterium, and it’s transient, meaning it passes through your gut rather than establishing permanent colonies. This makes it particularly useful during antibiotic treatment, when you want temporary support without organisms that might be killed by the antibiotic. It’s designed for specific scenarios (antibiotic use, traveller’s diarrhoea, with anti-microbials) although it’s safet allows it to be used for general daily microbiota maintenance.
Can I take this with my antibiotics?
Yes, that’s actually when it’s most useful. Unlike bacterial probiotics that antibiotics might suppress, S. boulardii works effectively during antibiotic treatment because it’s not affected by the antibiotic. Many practitioners recommend starting it when you begin your antibiotic course and continuing for 2 weeks after completion.
Why doesn’t this need refrigeration like other probiotics?
Yomogi uses lyophilisation (freeze-drying) technology to stabilise the yeast cells, making them viable at room temperature. This is a significant practical advantage for travel or warm climates, and it means the product maintains its potency without cold-chain dependency.
How long should I take this for?
This depends on your situation. For antibiotic-associated diarrhoea, most people use it during the antibiotic course plus 2 weeks after. For traveller’s diarrhoea prevention, start 5 days before travel and continue during your trip. It’s not typically used as indefinite daily support like multi-strain probiotics; it’s more targeted to specific situations.
Is this suitable for children?
Children over 6 years can take 1 capsule once or twice daily as directed. Children aged 2-6 years can use it if the capsule is opened and contents stirred into food or liquid. Children under 2 years and infants should not use this product.
Warnings & Storage
Do not use if: Blister backing is damaged or broken, you are hypersensitive or allergic to Saccharomyces cerevisiae or yeast, you are immunocompromised or hospitalised with serious illness, you have a central venous catheter, you are pregnant or breastfeeding, you have lactose intolerance.
Cautions: If symptoms persist, talk to your healthcare professional. Seek medical advice if diarrhoea persists for more than 6 hours in infants under 6 months, 12 hours in children under 3 years, 24 hours in children aged 3-6 years, or 48 hours in adults and children over 6 years. Contains lactose.
Storage: Store in a cool, dry place away from direct sunlight. No refrigeration required.
Always consult your healthcare professional before use if you have any pre-existing conditions or are taking medications.
| Weight | 0.041 kg |
|---|---|
| Dimensions | 6.6 × 6.2 × 10.6 cm |
| Size | 20 caps, 50 caps |
Brand
Evidence Based Probiotics
Evidence Based Probiotics Supplements Australia
Evidence Based Probiotics is an Australian supplier carrying a small, deliberately selected range of probiotic products - each built around a single, named strain with its own independent research history. The range currently includes two products: Yomogi, a yeast-based probiotic, and Mutaflor, a bacterial probiotic with an unusually long clinical record.
The distinguishing feature of this range is strain specificity. Both products are defined by exact strain identity - S. boulardii HANSEN CBS 5926 and E. coli Nissle 1917 - rather than species-level generics. This matters because the research literature attaches to the specific isolate, not the broader species, meaning the evidence base applies directly to what is in the product.
| Product Range | Primary Application |
|---|---|
| Yomogi S. boulardii (HANSEN CBS 5926) | Short-term gut support, periods of antibiotic use, acute gut disruption |
| Mutaflor (E. coli Nissle 1917) | Gut microbiome restoration, longer-term gut resilience |
The practical question for most people is not whether to use a specific probiotic strain - it is which one suits the situation. These two products serve different roles and are not interchangeable.
Why Evidence Based Probiotics' approach is different
Most probiotic products identify their contents by species name only - for example, "Saccharomyces boulardii" or "Lactobacillus acidophilus" - without naming the specific isolate. Different isolates within the same species can behave differently: they have different surface structures, interact with the gut lining differently, and have been studied for different applications. CBS 5926 is the pharmaceutical reference strain for S. boulardii - the isolate used in the majority of clinical trials on this species - which means that when you read published research on S. boulardii, it is almost always CBS 5926 that was tested.
E. coli Nissle 1917 is a non-pathogenic commensal strain - meaning it does not cause illness and belongs to the category of E. coli that naturally inhabits a healthy gut, not the enterotoxigenic strains associated with food contamination. The "1917" in the name is the actual year of isolation; this specific strain has been in continuous clinical study since then, making it one of the most thoroughly documented probiotic organisms in existence. Both strains have strain-specific production standards that govern how they are grown, stabilised, and packaged - standards that do not apply to generic species-level products.
The Evidence Based Probiotics range at Fairfield Nutrition
| Product | Best For | Key Ingredient(s) |
|---|---|---|
| Yomogi S. boulardii Probiotic | Gut disruption during or after antibiotic use, acute gut imbalance, travel-related gut stress | Saccharomyces cerevisiae (boulardii) HANSEN CBS 5926 |
| Mutaflor Probiotic | Gut microbiome restoration, longer-term gut resilience, post-disruption gut environment support | Escherichia coli Nissle 1917 (non-pathogenic commensal strain) |
The choice between these two products comes down to the nature of the probiotic and the intended timeframe. Yomogi is yeast-based, which means it is unaffected by antibiotics and suits shorter, targeted courses - it is often used during or immediately after antibiotic therapy. Mutaflor is bacterial and better suited to longer-term support aimed at establishing or restoring a stable gut environment. The two are sometimes used sequentially, but neither functions as a general-purpose probiotic blend - each has a specific evidence base that shapes when and how it is used.
Why shop Evidence Based Probiotics at Fairfield Nutrition
We don't stock everything - we stock what we'd use. Evidence Based Probiotics products are stocked at Fairfield because both strains represent the benchmark references in their respective research fields - CBS 5926 and Nissle 1917 are the specific isolates the published clinical literature is built around, not proxies or comparators.
Mutaflor is not widely available in Australia. It requires cold-chain handling throughout the supply chain and has specific import and storage requirements. Stocking it is a deliberate choice driven by the depth of the Nissle 1917 evidence base - this is a product that is genuinely difficult to source reliably in this market, and that difficulty does not change the clinical case for it.
Yomogi is sourced to the HANSEN CBS 5926 pharmaceutical specification - the same strain standard used in the majority of published S. boulardii trials. Not all S. boulardii products in the Australian market specify their strain to this level. When the product matches the research strain, the published data applies directly.
All Evidence Based Probiotics products stocked at Fairfield Nutrition are shown below.
